Active Stocks: IGI Laboratories, Inc. (NYSEMKT:IG), Ford Motor Company (NYSE:F), Albany International Corp. (NYSE:AIN), AbbVie Inc. (NYSE:ABBV), JDS Uniphase Corporation (NASDAQ:JDSU)

IGI Laboratories, Inc. (NYSEMKT:IG) belongs to Healthcare sector. Its net profit margin is 31.10% and weekly performance is 5.69%. On last trading day company shares ended up $6.69. IGI Laboratories, Inc. (NYSEMKT:IG) distance from 50-day simple moving average (SMA50) is 10.82%. On July 9, IGI Laboratories, Inc. (NYSEMKT:IG), announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 23, 2015 to discuss the 2nd quarter 2015 results.

Ford Motor Company (NYSE:F) shares increased 1.05% in last trading session and ended the day at $14.48. F Gross Margin is 12.80% and its return on assets is 1.50%. Ford Motor Company (NYSE:F) quarterly performance is -8.82%. The Board of Directors of Ford Motor Company (NYSE:F) declared a third quarter dividend of $0.15 per share on the company’s outstanding Class B and common stock. The third quarter dividend is the same level as the dividends paid in the first and second quarters of 2015, and a 20 percent increase from the dividends paid during each quarter of 2014.

On 10 July, Albany International Corp. (NYSE:AIN) shares increased 0.95% and was closed at $39.46. AIN EPS growth in last 5 year was 31.00%. Albany International Corp. (NYSE:AIN) year to date (YTD) performance is 4.73%. Albany International Corp. (NYSE:AIN) announced oday that it expects to record a second-quarter charge of approximately $14 million associated with a revision in the estimated profitability of a legacy contract in the Albany Engineered Composites segment (AEC).

AbbVie Inc. (NYSE:ABBV) ended the last trading day at $69.23. Company weekly volatility is calculated as 1.75% and price to cash ratio as 13.92. AbbVie Inc. (NYSE:ABBV) showed a weekly performance of 1.50%. AbbVie Inc. (NYSE:ABBV) announced the European Commission has granted marketing authorization for IMBRUVICA (ibrutinib) for the treatment of Waldenstrom’s macroglobulinemia, a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. AbbVie said the approval triggers a $20 million milestone payment from Janssen.

JDS Uniphase Corporation (NASDAQ:JDSU) shares increased 0.45% in last trading session and ended the day at $11.09. JDSU Gross Margin is 45.90% and its return on assets is -3.20%. JDS Uniphase Corporation (NASDAQ:JDSU) quarterly performance is -15.15%. JDS Uniphase Corporation (NASDAQ:JDSU) announced that it continues to expect to spin off its communications and commercial optical products (“CCOP”) business into a separate, publicly-traded company, Lumentum Holdings Inc. (“Lumentum”), in the third calendar quarter of 2015. Existing filings with the Securities and Exchange Commission indicate a distribution date of July 26, 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *